Blackrock Neurotech

An early feasibility study followed five people with spinal cord injury, each implanted with two Blackrock NeuroPort arrays in somatosensory cortex. Across two to 10 years of implantation, more than 168 million intracortical stimulation pulses were delivered over 27 combined implant-years without a serious adverse event or direct harm to electrode health. An average of 64% ± 13% of electrodes still evoked touch, including 60% after 10 years in one participant.

Johns Hopkins University has launched the INTENT clinical trial to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different brain areas, enabling adults with disabling paralysis to control assistive devices and receive feedback. The trial is now recruiting participants with conditions including tetraplegia, ALS, brain stem stroke, and spinal cord injury. Johns Hopkins is a leading U.S. research university whose medical school is renowned in neuroscience. The trial was first posted on ClinicalTrials.gov on April 13, 2026, and is currently recruiting.

The FDA granted Breakthrough Device designation to Blackrock Neurotech's MoveAgain BCI System on November 16, 2021. The investigational system combines an implanted array, neural decoding and wireless output with the goal of allowing people with severe paralysis to control digital and assistive devices. The designation can expedite development and review but is not market approval.